The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for ...

Explore JANX's promising early data in prostate cancer immunotherapy. Understand market challenges, buyout rumors, and ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

Millions have kidney disease without knowing it. Learn the 9 warning signs of CKD, who's at risk, and the most effective tips ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Most EGFR-mutated NSCLCs show some level of HER3 expression, but for now there are no HER3 directed therapies approved for NSCLC or any other form of cancer. The trial – called HERTHENA-Lung02 ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by the American Heart Association, a global force changing the future ...